SC012 - Brizo™
The prostate gland is the male organ that aids in the production of semen, located beneath the urinal bladder and surrounds the urethra. As men age, a common process of the prostate gland benign enlargement (non-cancerous) occurs, often referred to as benign prostate hyperplasia, or BPH.  Prostate gland enlargement leads to bothersome urinary symptoms such as: pressure on the urethra causing difficulty in urinating, abnormally frequent urination (both day and night), a perpetual
urgent need to urinate and at times presence of blood in the urine.
With the ever-increasing proportion of the population over 65 years of age worldwide,
BPH is becoming an increasingly important medical problem in this millennium.

The prostate enlargement, although non-cancerous, can have a profoundly negative impact on men’s quality of life, often causing them to limit or avoid basic activities of daily living.  Many men who develop BPH will seek treatment for bothersome lower urinary tract symptoms.
Available treatment options directed at decreasing symptoms and improving quality of life include herbal or medical therapy, minimally invasive therapy, and surgical intervention. The different treatment options have been demonstrated to improve symptoms in patients with BPH; however, they are not all equally efficacious and are often associated with an increased risk of side effects or complications.

The mechanism of action of SC012 (Brizo™) targets several pathways that are at the base of BPH:

  • SC012 (Brizo™) activates and bonds to ERβ (agonistic activity) which is an important modulator of prostatic growth. By bonding to ERβ, Brizo™ regulates Androgen Receptors (AR) and prostatic growth and acts to restrain the stimulatory action of ERα, where Brizo™ bonds and blocks (antagonist activity), reducing/limiting prostatic growth.
  • Brizo™ bonds and blocks Androgen Receptors (antagonistic effect), blocking the ability of Dihydrotestosterone (DHT) to attach to the AR and encourage prostate proliferation.
Brizo ™ provides a completely fresh approach for the management of BPH.
The combined effect of the different activities reduces the pressure on the urethra, easing urine flow, and decreases the prostate size. A significant beneficial effect of
Brizo™ on the bothersome symptoms can be felt within the 1st month of treatment, which progresses with longer intake.

The improvement is felt by lessening of waking up in the middle of the night in order to urinate, significant ease of urination, full voidance…

Within 90 days a significant reduction in the prostate size can be seen.


Home   |   About   |   R&D   |   Pipeline   |   Media   |   Investors   |   Contact